HIV Disease Coverage Forecast and Market Analysis to 2024 - ResearchAndMarkets.com

DUBLIN--()--The "HIV Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot

  • B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
  • TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
  • HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
  • Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
  • B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.

Key Topics Covered:

FORECAST: HIV (Published on 22 December 2017)

Overview

Executive Summary

Market Dynamics

Forecast And Future Trends

Market Definition And Methodology

Primary Research Methodology

Bibliography

Product Profile: Atripla

Product Profile (Late Stage): B/F/Taf

Product Profile: Complera

Product Profile (Late Stage): Dor/3Tc/Tdf

Product Profile: Descovy

Product Profile: Genvoya

Product Profile: Isentress

Product Profile: Juluca

Product Profile: Odefsey

Product Profile: Prezista Franchise

Product Profile: Reyataz Franchise

Product Profile: Stribild

Product Profile: Symtuza

Product Profile: Tivicay

Product Profile (Late Stage): Tivicay/Epivir

Product Profile: Triumeq

Product Profile: Truvada

Product Profile (Late Stage): Cabotegravir/Rilpivirine

Product Profile (Late Stage): Fostemsavir

TREATMENT: HIV (Published on 13 April 2018)

Overview

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Current Treatment Options

Treatment Guidelines

Prescribing Trends

Unmet Needs In Hiv

Impact Of Generics

EPIDEMIOLOGY: HIV (Published on 25 January 2019)

Overview

Disease Background

Methodology

Forecast

Bibliography

Appendix: Additional Sources

MARKETED DRUGS: HIV (Published on 22 December 2017)

Overview

Executive Summary

Product Overview

Product Profile: Atripla

Product Profile: Complera

Product Profile: Descovy

Product Profile: Genvoya

Product Profile: Isentress

Product Profile: Juluca

Product Profile: Odefsey

Product Profile: Prezista Franchise

Product Profile: Reyataz Franchise

Product Profile: Stribild

Product Profile: Symtuza

Product Profile: Tivicay

Product Profile: Triumeq

Product Profile: Truvada

PIPELINE: HIV (Published on 22 December 2017)

Overview

Executive Summary

Clinical Pipeline Overview

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): B/F/Taf

Product Profile (Late Stage): Dor/3Tc/Tdf

Product Profile (Late Stage): Tivicay/Epivir

Product Profile (Late Stage): Cabotegravir/Rilpivirine

Product Profile (Late Stage): Fostemsavir

For more information about this report visit https://www.researchandmarkets.com/r/yw3a0d

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: HIV/AIDS Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: HIV/AIDS Drugs